Patents Assigned to Lpath, Inc.
  • Compositions and methods for binding sphingosine-1-phosphate
    Patent number: 8026342
    Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: September 27, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Nucleic acids coding for humanized antibodies for binding sphingosine-1-phosphate
    Patent number: 7956173
    Abstract: The present invention relates to anti-S1P agents, particularly humanized monoclonal antibodies (and antigen binding fragments thereof) specifically reactive with S1P, compositions containing such antibodies (or fragments), and the use of such antibodies (or fragments), for example, to treat diseases and conditions associated with aberrant levels of S1P.
    Type: Grant
    Filed: October 24, 2008
    Date of Patent: June 7, 2011
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Compositions and methods for the treatment and prevention of cancer, angiogenesis, and inflammation
    Patent number: 7901682
    Abstract: Methods and compositions are disclosed that are useful for the prevention and/or treatment of cancer, angiogenesis, and inflammation. The beneficial effects of the compositions and methods are achieved through the use of pharmaceutical compositions that include agents that bind sphingolipids or sphingolipid metabolites. In one embodiment the agent is an antibody or antibody derivative. In some embodiments, the agent is a receptor of a sphingolipid or a sphingolipid metabolite. Also disclosed are methods for identifying and isolating therapeutic agents.
    Type: Grant
    Filed: December 13, 2006
    Date of Patent: March 8, 2011
    Assignee: Lpath, Inc.
    Inventor: Roger A. Sabbadini
  • Methods for decreasing immune response and treating immune conditions
    Patent number: 7862812
    Abstract: The present invention relates to compositions and methods for decreasing an immune response in an animal comprising administering to said animal an agent that binds a bioactive lipid and reduces the effective concentration of said bioactive lipid. Also provided are methods for treating diseases or conditions, including autoimmune disorders, which are characterized by an aberrant, excessive or undesired immune response. The methods of the invention utilize agents that bind bioactive lipids and are capable of decreasing the effective concentration of the bioactive lipid. In some embodiments, the agent is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: January 4, 2011
    Assignee: Lpath, Inc.
    Inventor: Roger A. Sabbadini
  • Compositions and methods for binding sphingosine-1-phosphate
    Patent number: 7829674
    Abstract: The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: November 9, 2010
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, William A. Garland, Genevieve Hansen, Steven Tarran Jones, David Gareth Williams
  • Compositions and methods for the treatment and prevention of hyperproliferative diseases
    Patent number: 7794713
    Abstract: Monotherapies and combination therapies for treating hyperproliferative disorders are described, as are compositions for performing such methods.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: September 14, 2010
    Assignee: Lpath, Inc.
    Inventors: Roger A. Sabbadini, Amy L. Cavalli, William A. Garland